2023
SARS-CoV-2 mRNA vaccines decouple anti-viral immunity from humoral autoimmunity
Jaycox J, Lucas C, Yildirim I, Dai Y, Wang E, Monteiro V, Lord S, Carlin J, Kita M, Buckner J, Ma S, Campbell M, Ko A, Omer S, Lucas C, Speake C, Iwasaki A, Ring A. SARS-CoV-2 mRNA vaccines decouple anti-viral immunity from humoral autoimmunity. Nature Communications 2023, 14: 1299. PMID: 36894554, PMCID: PMC9996559, DOI: 10.1038/s41467-023-36686-8.Peer-Reviewed Original ResearchConceptsVaccine-associated myocarditisAutoimmune patientsAutoantibody reactivitySARS-CoV-2 mRNA vaccinationVaccine-related adverse effectsSARS-CoV-2 immunitySARS-CoV-2 infectionAcute COVID-19Development of autoantibodiesCOVID-19 patientsAnti-viral immunityVirus-specific antibodiesCOVID-19 vaccineCOVID-19Humoral autoimmunityMRNA vaccinationAutoantibody responsePost vaccinationAutoantibody developmentAutoimmune diseasesHumoral responseHealthy individualsPatientsAntigen profilingAdverse effects
2020
SalivaDirect: A simplified and flexible platform to enhance SARS-CoV-2 testing capacity
Vogels CBF, Watkins AE, Harden CA, Brackney DE, Shafer J, Wang J, Caraballo C, Kalinich CC, Ott IM, Fauver JR, Kudo E, Lu P, Venkataraman A, Tokuyama M, Moore AJ, Muenker MC, Casanovas-Massana A, Fournier J, Bermejo S, Campbell M, Datta R, Nelson A, Team Y, Anastasio K, Askenase M, Batsu M, Bickerton S, Brower K, Bucklin M, Cahill S, Cao Y, Courchaine E, DeIuliis G, Earnest R, Geng B, Goldman-Israelow B, Handoko R, Khoury-Hanold W, Kim D, Knaggs L, Kuang M, Lapidus S, Lim J, Linehan M, Lu-Culligan A, Martin A, Matos I, McDonald D, Minasyan M, Nakahata M, Naushad N, Nouws J, Obaid A, Odio C, Oh J, Omer S, Park A, Park H, Peng X, Petrone M, Prophet S, Rice T, Rose K, Sewanan L, Sharma L, Shaw A, Shepard D, Smolgovsky M, Sonnert N, Strong Y, Todeasa C, Valdez J, Velazquez S, Vijayakumar P, White E, Yang Y, Dela Cruz C, Ko A, Iwasaki A, Krumholz H, Matheus J, Hui P, Liu C, Farhadian S, Sikka R, Wyllie A, Grubaugh N. SalivaDirect: A simplified and flexible platform to enhance SARS-CoV-2 testing capacity. Med 2020, 2: 263-280.e6. PMID: 33521748, PMCID: PMC7836249, DOI: 10.1016/j.medj.2020.12.010.Peer-Reviewed Original ResearchConceptsEmergency use authorizationSARS-CoV-2 testingSARS-CoV-2 screeningSARS-CoV-2 testing capacitySupply chain shortagesHospital cohortNasopharyngeal swabsHealthy individualsDrug AdministrationHigh positive agreementQRT-PCR assaysDiagnostic testsU.S. FoodSafe reopeningTesting capacityGlobal healthPositive agreementFast GrantLower ratesSalivaNucleic acid extractionSwabsValid alternativeAssay costsCollection tubes
2001
Evaluation of Recombinant Leptospira Antigen-Based Enzyme-Linked Immunosorbent Assays for the Serodiagnosis of Leptospirosis
Flannery B, Costa D, Carvalho F, Guerreiro H, Matsunaga J, Da Silva E, Ferreira A, Riley L, Reis M, Haake D, Ko A. Evaluation of Recombinant Leptospira Antigen-Based Enzyme-Linked Immunosorbent Assays for the Serodiagnosis of Leptospirosis. Journal Of Clinical Microbiology 2001, 39: 3303-3310. PMID: 11526167, PMCID: PMC88335, DOI: 10.1128/jcm.39.9.3303-3310.2001.Peer-Reviewed Original ResearchConceptsEnzyme-linked immunosorbent assayIgG enzyme-linked immunosorbent assaySerodiagnosis of leptospirosisHealthy individualsImmunosorbent assayTest-positive individualsCases of leptospirosisHigh-incidence regionsLyme disease patientsMicroscopic agglutination testConvalescent phaseHepatitis patientsAcute phaseDengue patientsDisease patientsPatient seraHealthy residentsLeptospira antigensCutoff valueDiagnostic utilityPatientsAgglutination testUseful antigenLeptospirosisAntigenLeptospiral Proteins Recognized during the Humoral Immune Response to Leptospirosis in Humans
Guerreiro H, Croda J, Flannery B, Mazel M, Matsunaga J, Reis M, Levett P, Ko A, Haake D. Leptospiral Proteins Recognized during the Humoral Immune Response to Leptospirosis in Humans. Infection And Immunity 2001, 69: 4958-4968. PMID: 11447174, PMCID: PMC98588, DOI: 10.1128/iai.69.8.4958-4968.2001.Peer-Reviewed Original ResearchConceptsHumoral immune responseImmune responseNatural infectionLeptospiral proteinsInfection-associated antigenConvalescent-phase seraPositive reactionConvalescent phaseHumoral responseHealthy individualsHuman leptospirosisControl individualsVaccine designImmunodominant antigensQuantitative immunoblot analysisTwo-dimensional immunoblotsProtein antigensPathogenic leptospiral strainsGenus LeptospiraInfectionAntigenLeptospirosisSerumImmunodominant proteinsPatients